Latest

neuropharmacology

This shows a brain with a neutral network spreading from the PFC. A drink glass is behind the brain.

·August 16, 2025·5 min read

Boosting Prefrontal Dopamine Shows Promise in Cutting Alcohol Use

A new study reveals that tolcapone, a dopamine-enhancing drug, strengthens brain circuits involved in self-control while reducing alcohol intake in people with alcohol use disorder (AUD). The drug boosts activity in the inferior frontal gyrus, part of the prefrontal cortex, which supports inhibitory control.

Featured Neurology Neuroscience

·August 14, 2025·10 min read

Could Restoring Lithium Levels Help Prevent Alzheimer’s Disease?

A decade-long investigation has revealed that natural lithium in the brain helps shield against Alzheimer’s disease by maintaining healthy function across all major brain cell types. Researchers found that lithium loss is one of the earliest brain changes in Alzheimer’s, often occurring before noticeable symptoms.

Featured Genetics Neurology Neuroscience

·August 11, 2025·5 min read

Reshaping Nuclear Speckles Could Halt Alzheimer’s

A groundbreaking study reveals that reshaping nuclear speckles — tiny structures inside cell nuclei that regulate protein maintenance — could be a novel way to treat proteinopathies like Alzheimer’s, Parkinson’s, and prion diseases. Researchers found that pyrvinium pamoate, an existing FDA-approved drug, alters the surface tension of nuclear speckles, making them less round and more effective at supporting proteostasis.

This shows a Brain surrounded by glial cells.

Featured Neuroscience Psychology

·August 1, 2025·6 min read

New Drug Targets Brain Glial Cells to Reverse PTSD Symptoms

A new study reveals that astrocyte-derived GABA, not neuronal activity, plays a central role in PTSD by impairing the brain’s ability to extinguish traumatic memories. Researchers found this excess GABA originates from the enzyme MAOB in astrocytes and disrupts fear regulation in the medial prefrontal cortex.

Autism Featured Neurology Neuroscience

·July 15, 2025·9 min read

No Link Found Between Aluminum in Vaccines and Autism, ADHD

A massive Danish study of over 1.2 million children has found no evidence that aluminum in early childhood vaccines increases the risk of neurological, autoimmune, or allergic disorders. Researchers analyzed 50 chronic conditions — including autism spectrum disorder (ASD), ADHD, asthma, and juvenile arthritis — and found no association with cumulative aluminum exposure from vaccines given before age two.

Brain Cancer Featured Neuroscience Visual Neuroscience

·July 14, 2025·4 min read

Cancer Drug Shows Promise In Treating AMD Vision Loss

Scientists have discovered that a locally developed cancer drug, PRL3-zumab, may offer a groundbreaking treatment for two major causes of blindness: wet age-related macular degeneration and diabetic retinopathy. Pre-clinical studies showed that intravenous PRL3-zumab reduced abnormal eye blood vessel leakage by 86% more than standard eye injections, with fewer risks.

Featured Neurology Neuroscience

·July 13, 2025·5 min read

Weekly Injection Could Revolutionize Parkinson’s Treatment

Researchers have developed a long-acting weekly injection that delivers steady doses of levodopa and carbidopa, potentially transforming care for Parkinson’s disease. The biodegradable injectable maintains consistent drug levels, reducing the need for multiple daily pills and improving patient adherence.

Featured Neurology Neuroscience

·July 11, 2025·5 min read

Common Pain Medication Linked to Cognitive Decline Risk

A large U.S. medical records study has found that adults prescribed gabapentin six or more times for chronic low back pain face significantly higher risks of dementia (29%) and mild cognitive impairment (85%) within 10 years. The risks were especially pronounced in younger adults aged 35–64, where rates of cognitive decline more than doubled or tripled compared to those not on the drug.

Featured Neurology Neuroscience

·July 1, 2025·5 min read

Cough Medicine Shows Promise in Slowing Parkinson’s Dementia

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia. The 12-month study found that the drug stabilized psychiatric symptoms, protected against brain damage, and even improved cognition in genetically at-risk participants.

Featured Genetics Neurology Neuroscience

·June 30, 2025·6 min read

Mimicking Exercise in the Brain Could Slow Cognitive Decline

While physical activity is known to slow cognitive decline in Alzheimer’s disease, many patients are unable to exercise due to frailty or advanced symptoms. A new study identifies a specific gene, ATPPIF1, that is reactivated through exercise and supports neuroplasticity in the brain.

This shows a person holding their head in pain.

Featured Neurology Neuroscience

·June 24, 2025·3 min read

GLP-1 Drug Cuts Migraine Days in Half

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and chronic migraine. Participants reported an average of 11 fewer headache days per month, alongside improved disability scores and quality of life.

Featured Neurology Neuroscience

·June 18, 2025·5 min read

RyR1 Channel Triggers Sedation from Anesthetics

A new study uncovers the long-elusive mechanism of inhalational anesthetics by identifying the RyR1 calcium channel as a key molecular target. Researchers demonstrated that anesthetics like isoflurane activate RyR1 to trigger calcium release from the endoplasmic reticulum, a crucial step in inducing general anesthesia.